Related Experiment Videos
Peptide-based immunotherapy: a novel strategy for allergic disease
1Faculty of Medicine, Imperial College, Department of Allergy and Clinical Immunology, Respiratory Immunology Group,Rm 360, Sir Alexander Fleming Building,Faculty of Medicine, Imperial College, London SW7 2AZ, UK.
Expert Review of Vaccines
|December 24, 2005
Summary
New peptide vaccines target T-cells to treat allergies, reducing side effects. This approach shows promise for inducing immune tolerance and may also benefit autoimmune disease treatment.
Area of Science:
- Immunology
- Allergy Research
- Vaccine Development
Background:
- Chronic allergic diseases involve T-cell mediated immune responses.
- Current whole allergen immunotherapy can cause adverse events.
- Novel peptide-based vaccines offer a targeted approach.
Purpose of the Study:
- To evaluate the safety and efficacy of synthetic allergen-derived peptide vaccines.
- To investigate the mechanism of tolerance induction by peptide epitopes.
- To explore the potential of epitope-specific therapy for allergic and autoimmune diseases.
Main Methods:
- Clinical trials using short, synthetic, allergen-derived peptides.
- Analysis of T-cell epitope interactions with immunoglobulin E.
- Assessment of regulatory T-cell induction and expansion.
Main Results:
- Peptide vaccines demonstrate safety and efficacy in clinical trials.
- Reduced systemic, immunoglobulin E-mediated adverse events compared to whole allergen immunotherapy.
- Evidence suggests peptide therapy induces antigen-specific regulatory T-cells.
Conclusions:
- Peptide epitope therapy is a promising novel treatment for allergic diseases with fewer adverse events.
- This approach has the potential to significantly impact allergy management and prevalence.
- Epitope-specific therapy principles may be applicable to autoimmune disease treatment.